Impact of abnormal second-trimester maternal serum single, Double, and triple screening on patient choices about prenatal diagnosi

Donna L B Lowry, Stephanie A. Campbell, Eric L. Krivchenia, Elaina Dvorin, Debra Duquette, Mark I. Evans*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

The development of multiple-marker biochemical screening has increased the percentage of aneuploidies detected for all age groups and has also increased the abnormality/amniocentesis ratio from about 1 in 85 for maternal serum α-fetoprotein alone (single screening) to about 1 in 50 for either maternal serum α-fetoprotein plus human chorionic gonadotropin (double screening) or maternal serum α-fetoprotein combined with human chorionic gonadotropin and unconjugated estriol (triple screening). We evaluated the decisions to have or decline amniocentesis of 985 patients ‘at risk’ by either single, double, or triple screening, as multiple markers were phased in over a 3-year period. The patient acceptance of the procedure did not change (approximately 80%) either by actual risk or type of biochemical screening. The labeling of ‘at risk’ status is more important than actual numerical risks, and the patient perception of risk status must be considered in counseling.

Original languageEnglish (US)
Pages (from-to)286-289
Number of pages4
JournalFetal Diagnosis and Therapy
Volume10
Issue number5
DOIs
StatePublished - Jan 1 1995

Keywords

  • Alpha-fetoprotein
  • Aneuploidy
  • Multiple-marker biochemical screening

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Embryology
  • Radiology Nuclear Medicine and imaging
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Impact of abnormal second-trimester maternal serum single, Double, and triple screening on patient choices about prenatal diagnosi'. Together they form a unique fingerprint.

Cite this